{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:45:58Z","timestamp":1782002758632,"version":"3.54.5"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11095-025-03956-7","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:37:04Z","timestamp":1762213024000},"page":"2247-2262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drum Filling of Thin-Film Freeze-Dried Monoclonal Antibody Powder in UniDose Powder Nasal Spray System"],"prefix":"10.1007","volume":"42","author":[{"given":"Michael A.","family":"Sandoval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel O.","family":"Jara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupendra R.","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan B.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Robert O.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengrong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"3956_CR1","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/jmv.21823","volume":"82","author":"M Khadadah","year":"2010","unstructured":"Khadadah M, Essa S, Higazi Z, Behbehani N, Al-Nakib W. Respiratory syncytial virus and human rhinoviruses are the major causes of severe lower respiratory tract infections in Kuwait. J Med Virol. 2010;82:1462\u20137.","journal-title":"J Med Virol"},{"key":"3956_CR2","first-page":"195","volume":"21","author":"EJ Chow","year":"2023","unstructured":"Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. 2023;21:195\u2013210.","journal-title":"Nat Rev Microbiol"},{"issue":"166","key":"3956_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0051-2022","volume":"31","author":"C Cilloniz","year":"2022","unstructured":"Cilloniz C, Luna CM, Hurtado JC, Marcos M\u00c1, Torres A. Respiratory viruses: their importance and lessons learned from COVID-19. Eur Respir Rev. 2022;31(166):220051.","journal-title":"Eur Respir Rev"},{"key":"3956_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41579-021-00535-6","volume":"19","author":"NHL Leung","year":"2021","unstructured":"Leung NHL. Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol. 2021;19:528\u201345.","journal-title":"Nat Rev Microbiol"},{"key":"3956_CR5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174439","volume":"134","author":"M Chen","year":"2024","unstructured":"Chen M, Pekosz A, Villano JS, et al. Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants. J Clin Invest. 2024;134:e174439.","journal-title":"J Clin Invest"},{"key":"3956_CR6","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444\u20138.","journal-title":"Science"},{"key":"3956_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21:382\u201393.","journal-title":"Nat Rev Immunol"},{"key":"3956_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-med-061323-073837","volume":"76","author":"A Casadevall","year":"2025","unstructured":"Casadevall A, Focosi D. Lessons from the use of monoclonal antibodies to SARS-CoV-2 spike protein during the COVID-19 pandemic. Annu Rev Med. 2025;76:1\u201312.","journal-title":"Annu Rev Med"},{"key":"3956_CR9","doi-asserted-by":"publisher","first-page":"e458","DOI":"10.1016\/S2665-9913(22)00099-6","volume":"4","author":"T Goulenok","year":"2022","unstructured":"Goulenok T, Delaval L, Delory N, Fran\u00e7ois C, Papo T, Descamps D, et al. Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases. Lancet Rheumatol. 2022;4:e458\u201361.","journal-title":"Lancet Rheumatol"},{"key":"3956_CR10","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1286","volume":"176","author":"KE Kip","year":"2023","unstructured":"Kip KE, McCreary EK, Collins K, et al. Evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19. Ann Intern Med. 2023;176:M22-1286.","journal-title":"Ann Intern Med"},{"key":"3956_CR11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s41587-020-0732-8","volume":"38","author":"L DeFrancesco","year":"2020","unstructured":"DeFrancesco L. COVID-19 antibodies on trial. Nat Biotechnol. 2020;38:1242\u201352.","journal-title":"Nat Biotechnol"},{"key":"3956_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41586-021-03673-2","volume":"595","author":"Z Ku","year":"2021","unstructured":"Ku Z, Xie X, Hinton PR, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595:718\u201323.","journal-title":"Nature"},{"key":"3956_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1128\/CMR.12.3.383","volume":"12","author":"R Weltzin","year":"1999","unstructured":"Weltzin R, Monath TP. Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev. 1999;12:383\u201393.","journal-title":"Clin Microbiol Rev"},{"key":"3956_CR14","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1007\/s00253-021-11488-4","volume":"105","author":"HA Parray","year":"2021","unstructured":"Parray HA, Shukla S, Perween R, et al. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Appl Microbiol Biotechnol. 2021;105:6315\u201332.","journal-title":"Appl Microbiol Biotechnol"},{"key":"3956_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tips.2022.11.006","volume":"44","author":"MYT Chow","year":"2023","unstructured":"Chow MYT, Pan HW, Seow HC, Lam JKW. Inhalable neutralizing antibodies \u2013 promising approach to combating respiratory viral infections. Trends Pharmacol Sci. 2023;44:85\u201397.","journal-title":"Trends Pharmacol Sci"},{"key":"3956_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-94314-5","volume":"15","author":"AL Beukenhorst","year":"2025","unstructured":"Beukenhorst AL, Rice KL, Frallicciardi J, et al. Intranasal administration of a panreactive influenza antibody reveals Fc-independent mode of protection. Sci Rep. 2025;15:10309.","journal-title":"Sci Rep"},{"key":"3956_CR17","doi-asserted-by":"crossref","unstructured":"Emig CJ, Mena MA, Henry SJ, Vitug A, Ventura CJ, Fox D, et al. AUG-3387, a human-derived monoclonal antibody neutralizes SARS-CoV-2 variants and reduces viral load from therapeutic treatment of hamsters in vivo. BioRxiv. 2021;2021.10.12.464150.","DOI":"10.1101\/2021.10.12.464150"},{"key":"3956_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124511","volume":"662","author":"H Xu","year":"2024","unstructured":"Xu H, Sahakijpijarn S, Moon C, et al. Inhalable dry powders of a monoclonal antibody against SARS-CoV-2 virus made by thin-film freeze-drying. Int J Pharm. 2024;662:124511.","journal-title":"Int J Pharm"},{"key":"3956_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123892","volume":"653","author":"Y-S Yu","year":"2024","unstructured":"Yu Y-S, Xu H, AboulFotouh K, et al. Intranasal delivery of thin-film freeze-dried monoclonal antibodies using a powder nasal spray system. Int J Pharm. 2024;653:123892.","journal-title":"Int J Pharm"},{"key":"3956_CR20","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.2174\/1381612821666150820111134","volume":"21","author":"Y-W Lin","year":"2015","unstructured":"Lin Y-W, Wong J, Qu L, Chan H-K, Zhou Q. Powder production and particle engineering for dry powder inhaler formulations. Curr Pharm Des. 2015;21:3902\u201316.","journal-title":"Curr Pharm Des"},{"key":"3956_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3109\/03639045.2010.489561","volume":"37","author":"F Eskandar","year":"2011","unstructured":"Eskandar F, Lejeune M, Edge S. Low powder mass filling of dry powder inhalation formulations. Drug Dev Ind Pharm. 2011;37:24\u201332.","journal-title":"Drug Dev Ind Pharm"},{"key":"3956_CR22","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3109\/03639045.2012.728227","volume":"39","author":"JG Osorio","year":"2013","unstructured":"Osorio JG, Muzzio FJ. Effects of powder flow properties on capsule filling weight uniformity. Drug Dev Ind Pharm. 2013;39:1464\u201375.","journal-title":"Drug Dev Ind Pharm"},{"key":"3956_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijpharm.2016.11.010","volume":"516","author":"S Stranzinger","year":"2017","unstructured":"Stranzinger S, Faulhammer E, Calzolari V, Biserni S, Dreu R, \u0160ibanc R, et al. The effect of material attributes and process parameters on the powder bed uniformity during a low-dose dosator capsule filling process. Int J Pharm. 2017;516:9\u201320.","journal-title":"Int J Pharm"},{"key":"3956_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ijpharm.2014.07.050","volume":"473","author":"E Faulhammer","year":"2014","unstructured":"Faulhammer E, Fink M, Llusa M, Lawrence SM, Biserni S, Calzolari V, et al. Low-dose capsule filling of inhalation products: critical material attributes and process parameters. Int J Pharm. 2014;473:617\u201326.","journal-title":"Int J Pharm"},{"key":"3956_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010014","volume":"12","author":"A J\u00fcptner","year":"2019","unstructured":"J\u00fcptner A, Scherlie\u00df R. Spray dried formulations for inhalation\u2014meaningful characterisation of powder properties. Pharmaceutics. 2019;12:14.","journal-title":"Pharmaceutics"},{"key":"3956_CR26","unstructured":"United States Pharmacopeia National Formulary (USP-NF). USP <616>  bulk density of powders. [cited 2025 June 1]. USP-NF 2024. Available from: https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/our-work\/reference-standards\/20240927HSm99375.pdf"},{"key":"3956_CR27","unstructured":"United States Pharmacopeia National Formulary (USP-NF). USP <1174> powder flow. [cited 2025 June 1]. USP-NF 2024. Available from: https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/harmonization\/gen-chapter\/20230428HSm99885.pdf"},{"key":"3956_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jconrel.2018.10.020","volume":"292","author":"SG Thakkar","year":"2018","unstructured":"Thakkar SG, Warnken ZN, Alzhrani RF, Valdes SA, Aldayel AM, Xu H, et al. Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine. J Control Release. 2018;292:111\u20138.","journal-title":"J Control Release"},{"key":"3956_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124454","volume":"661","author":"W Tharanon","year":"2024","unstructured":"Tharanon W, Guo Y, Peerapattana J, Sun CC. A systematic comparison of four pharmacopoeial methods for measuring powder flowability. Int J Pharm. 2024;661:124454.","journal-title":"Int J Pharm"},{"key":"3956_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125919","volume":"682","author":"B Southard","year":"2025","unstructured":"Southard B, Melton K, Sandoval MA, Zaki R, Williams RO, Cui Z. Development of an inhalable dry powder of mycobacteriophage D29 using thin-film freeze-drying. Int J Pharm. 2025;682:125919.","journal-title":"Int J Pharm"},{"key":"3956_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121637","volume":"618","author":"S Hufnagel","year":"2022","unstructured":"Hufnagel S, Xu H, Sahakijpijarn S, Moon C, Chow LQM, Iii ROW, et al. Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying. Int J Pharm. 2022;618:121637.","journal-title":"Int J Pharm"},{"key":"3956_CR32","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-022-02461-z","volume":"24","author":"BR Giri","year":"2022","unstructured":"Giri BR, Maniruzzaman M. Fabrication of sustained-release dosages using powder-based three-dimensional (3D) printing technology. AAPS PharmSciTech. 2022;24:4.","journal-title":"AAPS PharmSciTech"},{"key":"3956_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122568","volume":"14","author":"MO Jara","year":"2022","unstructured":"Jara MO, Warnken ZN, Sahakijpijarn S, Thakkar R, Kulkarni VR, Christensen DJ, et al. Oral delivery of Niclosamide as an amorphous solid dispersion that generates amorphous nanoparticles during dissolution. Pharmaceutics. 2022;14:2568.","journal-title":"Pharmaceutics"},{"key":"3956_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122990","volume":"640","author":"Y-S Yu","year":"2023","unstructured":"Yu Y-S, AboulFotouh K, Xu H, Williams G, Suman J, Cano C, et al. Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders. Int J Pharm. 2023;640:122990.","journal-title":"Int J Pharm"},{"key":"3956_CR35","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1021\/acs.molpharmaceut.7b00702","volume":"15","author":"ZN Warnken","year":"2018","unstructured":"Warnken ZN, Smyth HDC, Davis DA, Weitman S, Kuhn JG, Williams RO. Personalized medicine in nasal delivery: the use of patient-specific administration parameters to improve nasal drug targeting using 3D-printed nasal replica casts. Mol Pharm. 2018;15:1392\u2013402.","journal-title":"Mol Pharm"},{"key":"3956_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123179","volume":"642","author":"J Li","year":"2023","unstructured":"Li J, Ma S, He X, Sun Y, Zhang X, Guan J, et al. Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler. Int J Pharm. 2023;642:123179.","journal-title":"Int J Pharm"},{"key":"3956_CR37","doi-asserted-by":"crossref","unstructured":"Zhou Q (Tony), Qu L, Gengenbach T, Larson I, Stewart PJ, Morton DAV. Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers. AAPS PharmSciTech 2013;14:38\u201344.","DOI":"10.1208\/s12249-012-9895-z"},{"key":"3956_CR38","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1002\/jps.21629","volume":"98","author":"P Begat","year":"2009","unstructured":"Begat P, Morton DAV, Shur J, Kippax P, Staniforth JN, Price R. The role of force control agents in high-dose dry powder inhaler formulations. J Pharm Sci. 2009;98:2770\u201383.","journal-title":"J Pharm Sci"},{"key":"3956_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.14356\/kona.2005014","volume":"23","author":"P Begat","year":"2014","unstructured":"Begat P, Price R, Harris H, Morton DAV, Staniforth JN. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. KONA Powder Part J. 2014;23:109.","journal-title":"KONA Powder Part J"},{"key":"3956_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17060784","volume":"17","author":"R-A Vlad","year":"2025","unstructured":"Vlad R-A, Pintea A, Pintea C, R\u00e9dai E-M, Antonoaea P, B\u00eersan M, et al. Hydroxypropyl methylcellulose\u2014a key excipient in pharmaceutical drug delivery systems. Pharmaceutics. 2025;17:784.","journal-title":"Pharmaceutics"},{"key":"3956_CR41","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1208\/s12249-012-9841-0","volume":"13","author":"J Curtis-Fisk","year":"2012","unstructured":"Curtis-Fisk J, Sheskey P, Balwinski K, Coppens K, Mohler C, Zhao J. Effect of formulation conditions on hypromellose performance properties in films used for capsules and tablet coatings. AAPS PharmSciTech. 2012;13:1170\u20138.","journal-title":"AAPS PharmSciTech"},{"key":"3956_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2023.120731","volume":"311","author":"C Jin","year":"2023","unstructured":"Jin C, Wu F, Hong Y, Shen L, Lin X, Zhao L, et al. Updates on applications of low-viscosity grade Hydroxypropyl methylcellulose in coprocessing for improvement of physical properties of pharmaceutical powders. Carbohydr Polym. 2023;311:120731.","journal-title":"Carbohydr Polym"},{"key":"3956_CR43","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","volume":"57","author":"MI Ugwoke","year":"2005","unstructured":"Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005;57:1640\u201365.","journal-title":"Adv Drug Deliv Rev"},{"key":"3956_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejps.2007.02.002","volume":"31","author":"FJ McInnes","year":"2007","unstructured":"McInnes FJ, O\u2019Mahony B, Lindsay B, Band J, Wilson CG, Hodges LA, et al. Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. Eur J Pharm Sci. 2007;31:25\u201331.","journal-title":"Eur J Pharm Sci"},{"key":"3956_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4103\/2231-4040.90876","volume":"2","author":"M Chaturvedi","year":"2011","unstructured":"Chaturvedi M, Kumar M, Pathak K. A review on mucoadhesive polymer used in nasal drug delivery system. J Adv Pharm Technol Res. 2011;2:215\u201322.","journal-title":"J Adv Pharm Technol Res"},{"issue":"3","key":"3956_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13030385","volume":"13","author":"M Trenkel","year":"2021","unstructured":"Trenkel M, Scherlie\u00df R. Nasal powder formulations: in-vitro characterisation of the impact of powders on nasal residence time and sensory effects. Pharmaceutics. 2021;13(3):385.","journal-title":"Pharmaceutics"},{"key":"3956_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120500","volume":"600","author":"VDN Bezzon","year":"2021","unstructured":"Bezzon VDN, Ferreira FF, Smith P, Benmore CJ, Byrn SR, de Araujo GLB. Amorphous dispersions of flubendazole in hydroxypropyl methylcellulose: formulation stability assisted by pair distribution function analysis. Int J Pharm. 2021;600:120500.","journal-title":"Int J Pharm"},{"key":"3956_CR48","unstructured":"U.S. Food and Drug Administration (FDA). ASTEPRO (azelastine hydrochloride) Nasal Spray. Prescribing information. 1996. Accessed January 16, 2025. [Internet]."},{"key":"3956_CR49","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/14787210.2021.1908127","volume":"19","author":"K Shmuel","year":"2021","unstructured":"Shmuel K, Dalia M, Tair L, Yaakov N. Low pH hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey. Expert Rev Anti-infect Ther. 2021;19:1325\u201330.","journal-title":"Expert Rev Anti-infect Ther"},{"key":"3956_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/v13122345","volume":"13","author":"K Bentley","year":"2021","unstructured":"Bentley K, Stanton RJ. Hydroxypropyl methylcellulose-based nasal sprays effectively inhibit in vitro SARS-CoV-2 infection and spread. Viruses. 2021;13:2345.","journal-title":"Viruses"},{"key":"3956_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42539-7","volume":"13","author":"T Imsuwansri","year":"2023","unstructured":"Imsuwansri T, Jongthitinon T, Pojdoung N, et al. Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers. Sci Rep. 2023;13:15648.","journal-title":"Sci Rep"},{"key":"3956_CR52","unstructured":"Raymond RC, Sheskey PJ, Quinn, ME. Handbook of pharmaceutical excipients. 6th ed.  London, UK and Washington, DC: Pharmaceutical Press and American Pharmacists Association. 2009."},{"key":"3956_CR53","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1208\/s12249-013-0007-5","volume":"14","author":"G Morin","year":"2013","unstructured":"Morin G, Briens L. The effect of lubricants on powder flowability for pharmaceutical application. AAPS PharmSciTech. 2013;14:1158\u201368.","journal-title":"AAPS PharmSciTech"},{"key":"3956_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16498","volume":"9","author":"DS Shah","year":"2023","unstructured":"Shah DS, Moravkar KK, Jha DK, Lonkar V, Amin PD, Chalikwar SS. A concise summary of powder processing methodologies for flow enhancement. Heliyon. 2023;9:e16498.","journal-title":"Heliyon"},{"key":"3956_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12249-013-0036-0","volume":"15","author":"A Crouter","year":"2014","unstructured":"Crouter A, Briens L. The effect of moisture on the flowability of pharmaceutical excipients. AAPS PharmSciTech. 2014;15:65\u201374.","journal-title":"AAPS PharmSciTech"},{"key":"3956_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121218","volume":"609","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Li X, Jasti BR. Role of physicochemical properties of some grades of hydroxypropyl methylcellulose on in vitro mucoadhesion. Int J Pharm. 2021;609:121218.","journal-title":"Int J Pharm"},{"key":"3956_CR57","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1002\/fsn3.1206","volume":"7","author":"R Ghadermazi","year":"2019","unstructured":"Ghadermazi R, Hamdipour S, Sadeghi K, Ghadermazi R, Asl AK. Effect of various additives on the properties of the films and coatings derived from hydroxypropyl methylcellulose\u2014a review. Food Sci Nutr. 2019;7:3363\u201377.","journal-title":"Food Sci Nutr"},{"issue":"1","key":"3956_CR58","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4155\/tde.10.1","volume":"1","author":"D Edwards","year":"2010","unstructured":"Edwards D. Applications of capsule dosing techniques for use in dry powder inhalers. Ther Deliv. 2010;1(1):195\u2013201.","journal-title":"Ther Deliv"},{"key":"3956_CR59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijpharm.2018.07.054","volume":"549","author":"S Ferrati","year":"2018","unstructured":"Ferrati S, Wu T, Kanapuram SR, Smyth HDC. Dosing considerations for inhaled biologics. Int J Pharm. 2018;549:58\u201366.","journal-title":"Int J Pharm"},{"key":"3956_CR60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijpharm.2018.01.055","volume":"540","author":"S Stranzinger","year":"2018","unstructured":"Stranzinger S, Faulhammer E, Scheibelhofer O, Calzolari V, Biserni S, Paudel A, et al. Study of a low-dose capsule filling process by dynamic and static tests for advanced process understanding. Int J Pharm. 2018;540:22\u201330.","journal-title":"Int J Pharm"},{"key":"3956_CR61","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ijpharm.2013.03.003","volume":"447","author":"H Grohganz","year":"2013","unstructured":"Grohganz H, Lee Y-Y, Rantanen J, Yang M. The influence of lysozyme on mannitol polymorphism in freeze-dried and spray-dried formulations depends on the selection of the drying process. Int J Pharm. 2013;447:224\u201330.","journal-title":"Int J Pharm"},{"issue":"3","key":"3956_CR62","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1021\/acs.molpharmaceut.1c00915","volume":"19","author":"M Li","year":"2022","unstructured":"Li M, Reichert P, Narasimhan C, Sorman B, Xu W, Cote A, et al. Investigating crystalline protein suspension formulations of Pembrolizumab from MAS NMR spectroscopy. Mol Pharm. 2022;19(3):936\u201352.","journal-title":"Mol Pharm"},{"key":"3956_CR63","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s11095-023-03473-5","volume":"40","author":"H Xu","year":"2023","unstructured":"Xu H, Moon C, Sahakijpijarn S, Dao HM, Alzhrani RF, Wang J, et al. Aerosolizable plasmid DNA dry powders engineered by thin-film freezing. Pharm Res. 2023;40:1141\u201352.","journal-title":"Pharm Res"},{"key":"3956_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081113","volume":"13","author":"AA Benetti","year":"2021","unstructured":"Benetti AA, Bianchera A, Buttini F, Bertocchi L, Bettini R. Mannitol polymorphs as carrier in DPIs formulations: isolation characterization and performance. Pharmaceutics. 2021;13:1113.","journal-title":"Pharmaceutics"},{"key":"3956_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2023.100031","volume":"2","author":"ZH Mok","year":"2024","unstructured":"Mok ZH. The effect of particle size on drug bioavailability in various parts of the body. Pharmaceutical Science Advances. 2024;2:100031.","journal-title":"Pharmaceutical Science Advances"},{"key":"3956_CR66","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-022-02278-w","volume":"23","author":"S Baxter","year":"2022","unstructured":"Baxter S, Myatt B, Stein S, et al. Spray pattern and plume geometry testing and methodology: an IPAC-RS working group overview. AAPS PharmSciTech. 2022;23:145.","journal-title":"AAPS PharmSciTech"},{"key":"3956_CR67","unstructured":"Center for Drug Evaluation and Research (CDER). Food and Drug Administration (FDA). OTHER REVIEW(S) for Application Number 210134Orig1s000 (BAQSIMI glucagon nasal powder). 2019. Accessed on February 22, 2025."},{"key":"3956_CR68","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1089\/jam.2007.0638","volume":"20","author":"MY Foo","year":"2007","unstructured":"Foo MY, Cheng Y-S, Su W-C, Donovan MD. The influence of spray properties on intranasal deposition. J Aerosol Med. 2007;20:495\u2013508.","journal-title":"J Aerosol Med"},{"key":"3956_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2022.924501","volume":"4","author":"C Rigaut","year":"2022","unstructured":"Rigaut C, Deruyver L, Goole J, Haut B, Lambert P. Instillation of a dry powder in nasal casts: parameters influencing the olfactory deposition with uni- and bi-directional devices. Front Med Technol. 2022;4:924501.","journal-title":"Front Med Technol"},{"key":"3956_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081213","volume":"13","author":"L Ding","year":"2021","unstructured":"Ding L, Brunaugh AD, Stegemann S, Jermain SV, Herpin MJ, Kalafat J, et al. A quality by design framework for capsule-based dry powder inhalers. Pharmaceutics. 2021;13:1213.","journal-title":"Pharmaceutics"},{"key":"3956_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061185","volume":"14","author":"R Gro\u00df","year":"2022","unstructured":"Gro\u00df R, Berkenfeld K, Schulte C, Ebert A, Sule S, Sule A, et al. State of the art in capsule-based dry powder inhalers: deagglomeration techniques and the consequences for formulation aerosolization. Pharmaceutics. 2022;14:1185.","journal-title":"Pharmaceutics"},{"key":"3956_CR72","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-020-01676-2","volume":"21","author":"JT Pinto","year":"2020","unstructured":"Pinto JT, Wutscher T, Stankovic-Brandl M, et al. Evaluation of the physico-mechanical properties and electrostatic charging behavior of different capsule types for inhalation under distinct environmental conditions. AAPS PharmSciTech. 2020;21:128.","journal-title":"AAPS PharmSciTech"},{"key":"3956_CR73","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.xphs.2023.02.010","volume":"112","author":"M Ibrahim","year":"2023","unstructured":"Ibrahim M, Wallace I, Ghazvini S, Manetz S, Cordoba-Rodriguez R, Patel SM. Protein aggregates in inhaled biologics: challenges and considerations. J Pharm Sci. 2023;112:1341\u20134.","journal-title":"J Pharm Sci"},{"key":"3956_CR74","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.tibtech.2014.05.005","volume":"32","author":"CJ Roberts","year":"2014","unstructured":"Roberts CJ. Therapeutic protein aggregation: mechanisms, design, and control. Trends Biotechnol. 2014;32:372\u201380.","journal-title":"Trends Biotechnol"},{"key":"3956_CR75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/08942680152484199","volume":"14","author":"YS Cheng","year":"2001","unstructured":"Cheng YS, Holmes TD, Gao J, Guilmette RA, Li S, Surakitbanharn Y, et al. Characterization of nasal spray pumps and deposition pattern in a replica of the human nasal airway. J Aerosol Med. 2001;14:267\u201380.","journal-title":"J Aerosol Med"},{"key":"3956_CR76","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s11095-005-7391-9","volume":"22","author":"Y Guo","year":"2005","unstructured":"Guo Y, Laube B, Dalby R. The effect of formulation variables and breathing patterns on the site of nasal deposition in an anatomically correct model. Pharm Res. 2005;22:1871\u20138.","journal-title":"Pharm Res"},{"key":"3956_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221330","volume":"14","author":"H Calmet","year":"2019","unstructured":"Calmet H, Inthavong K, Eguzkitza B, Lehmkuhl O, Houzeaux G, V\u00e1zquez M. Nasal sprayed particle deposition in a human nasal cavity under different inhalation conditions. PLoS ONE. 2019;14:e0221330.","journal-title":"PLoS ONE"},{"key":"3956_CR78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23:3\u201320.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3956_CR79","doi-asserted-by":"publisher","DOI":"10.1172\/jci148517","author":"JH Ahn","year":"2021","unstructured":"Ahn JH, Kim J, Hong SP, et al. Nasal ciliated cells are primary targets for SARS-CoV-2 replication in early stage of COVID-19. J Clin Investig. 2021. https:\/\/doi.org\/10.1172\/jci148517.","journal-title":"J Clin Investig"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03956-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03956-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03956-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:02:33Z","timestamp":1768932153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03956-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3956"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03956-7","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ZC and ROW have patent(s) and\/or patent applications related to thin-film freeze-drying of mAbs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}